Aarti Drugs Ltd Stock Price Today (NSE: AARTIDRUGS)
Fundamental Score
Aarti Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarti Drugs Ltd share price today is ₹319.75, down 3.05% on NSE/BSE as of 30 March 2026. Aarti Drugs Ltd (AARTIDRUGS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.80K (Cr). The 52-week high for AARTIDRUGS share price is ₹564.05 and the 52-week low is ₹312.00. At a P/E ratio of 19.07x, AARTIDRUGS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.69% and a debt-to-equity ratio of 0.39.
Aarti Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Aarti Drugs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Aarti Drugs Share Price: A Financial Analysis for Growth
The pharmaceutical industry is witnessing a significant shift towards API (Active Pharmaceutical Ingredient) manufacturing, driven by increasing global demand and supply chain diversification strategies. This makes a closer look at companies like Aarti Drugs particularly relevant. This financial analysis delves into the current standing of Aarti Drugs share price, which currently sits at ₹374.649994, using publicly available data and comparative metrics. We will observe the company’s valuation and profitability in relation to its peers.
Aarti Drugs' current Price-to-Earnings (PE) ratio of 19.07 suggests that the market values the company's earnings at a certain premium. When comparing this to sector peers such as Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd, investors can get a clearer understanding of where Aarti Drugs stands in terms of relative valuation. For instance,
Mankind Pharma Ltd may command a higher PE due to perceived stronger management quality, brand recognition, or future growth prospects. However, this is simply a comparative observation, not an endorsement.A crucial indicator of a company's efficiency and profitability is its Return on Capital Employed (ROCE). Aarti Drugs' ROCE of 13.09% reflects the return generated on the capital invested in the business. While seemingly decent, the strength of this ROCE in building a sustainable moat depends on the consistency of this return and its position relative to the company's cost of capital. A consistently higher ROCE than cost of capital means more value creation and increased competitive advantage in the long run.
In conclusion, this financial analysis provides an observational snapshot of Aarti Drugs based on publicly available data. The current Aarti Drugs share price reflects a specific market valuation, further illuminated by analyzing the PE ratio and ROCE. This is part of a broader, 80-parameter fundamental audit personally verified by Sweta Mishra, aimed at providing a comprehensive view of the company's financial health. It is important to note that this analysis is purely observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIDRUGS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 19.07 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (29.33%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Interest Coverage (7.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹164.97 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Weak Earnings Growth (4.46% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.03% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Aarti Drugs Ltd Financial Statements
Comprehensive financial data for Aarti Drugs Ltd including income statement, balance sheet and cash flow
About AARTIDRUGS (Aarti Drugs Ltd)
Aarti Drugs Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. With ...a strong emphasis on innovation and quality, the company operates through its subsidiaries, focusing on active pharmaceutical ingredients (APIs), crucial intermediates, specialized chemicals, and finished formulations. Their commitment to research and development is evident in their continuous efforts to enhance existing processes and introduce novel molecules, positioning them as a reliable partner for pharmaceutical companies worldwide. Aarti Drugs strives to uphold the highest standards of regulatory compliance and environmental responsibility in all aspects of their operations. The company's API portfolio encompasses a wide spectrum of therapeutic categories, including anti-inflammatory, antibiotic, and anti-infective agents. This extensive range allows Aarti Drugs to cater to the varied needs of their clientele, which includes generic pharmaceutical manufacturers and branded pharmaceutical companies. By vertically integrating their operations, from the production of key starting materials to the final API, Aarti Drugs maintains rigorous control over quality and supply chain efficiency. Their dedication to meeting stringent international quality standards has earned them a reputation for reliability and consistency in delivering high-quality products. Aarti Drugs extends its expertise beyond APIs, offering specialized chemical solutions tailored to the specific needs of its customers. Their commitment to providing comprehensive pharmaceutical solutions is further reinforced through their manufacturing and marketing of finished formulations. With a focus on affordability and accessibility, Aarti Drugs contributes to improving healthcare outcomes by offering cost-effective medications. Their dedication to innovation, quality, and customer satisfaction cements their position as a trusted and valuable player in the global pharmaceutical landscape.
Company Details
Key Leadership
Corporate Events
AARTIDRUGS Share Price: Frequently Asked Questions
What is the current share price of Aarti Drugs Ltd (AARTIDRUGS)?
As of 30 Mar 2026, 12:07 pm IST, Aarti Drugs Ltd share price is ₹319.75. The AARTIDRUGS stock has a market capitalisation of ₹3.80K (Cr) on NSE/BSE.
Is AARTIDRUGS share price Overvalued or Undervalued?
AARTIDRUGS share price is currently trading at a P/E ratio of 19.07x, compared to the industry average of 31.77x. Based on this relative valuation, the Aarti Drugs Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of AARTIDRUGS share price?
The 52-week high of AARTIDRUGS share price is ₹564.05 and the 52-week low is ₹312.00. These values are updated daily from NSE/BSE price data.
What factors affect the Aarti Drugs Ltd share price?
Key factors influencing AARTIDRUGS share price include quarterly earnings growth (Sales Growth: 9.10%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aarti Drugs Ltd a good stock for long-term investment?
Aarti Drugs Ltd shows a 5-year Profit Growth of 4.03% and an ROE of 12.69%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.39 before investing in AARTIDRUGS shares.
How does Aarti Drugs Ltd compare with its industry peers?
Aarti Drugs Ltd competes with major peers in the Pharmaceuticals. Investors should compare AARTIDRUGS share price P/E of 19.07x and ROE of 12.69% against the industry averages to determine competitive standing.
What is the P/E ratio of AARTIDRUGS and what does it mean?
AARTIDRUGS share price has a P/E ratio of 19.07x compared to the industry average of 31.77x. Investors pay ₹19 for every ₹1 of annual earnings.
How is AARTIDRUGS performing according to Bull Run's analysis?
AARTIDRUGS has a Bull Run fundamental score of 50.2/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does AARTIDRUGS belong to?
AARTIDRUGS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aarti Drugs Ltd share price.
What is Return on Equity (ROE) and why is it important for AARTIDRUGS?
AARTIDRUGS has an ROE of 12.69%, which shows decent profitability but room for improvement. ROE measures how efficiently Aarti Drugs Ltd generates profits from shareholders capital.
How is AARTIDRUGS debt-to-equity ratio and what does it indicate?
AARTIDRUGS has a debt-to-equity ratio of 0.39, which indicates moderate leverage that should be monitored.
What is AARTIDRUGS dividend yield and is it a good dividend stock?
AARTIDRUGS offers a dividend yield of 0.24%, meaning you receive ₹0.24 annual dividend for every ₹100 invested in Aarti Drugs Ltd shares.
How has AARTIDRUGS share price grown over the past 5 years?
AARTIDRUGS has achieved 5-year growth rates of: Sales Growth 5.74%, Profit Growth 4.03%, and EPS Growth 4.46%.
What is the promoter holding in AARTIDRUGS and why does it matter?
Promoters hold 54.72% of AARTIDRUGS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Aarti Drugs Ltd.
What is AARTIDRUGS market capitalisation category?
AARTIDRUGS has a market capitalisation of ₹3796 crores, placing it in the Small-cap category.
How volatile is AARTIDRUGS stock?
AARTIDRUGS has a beta of N/A. A beta > 1 suggests the Aarti Drugs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is AARTIDRUGS operating profit margin trend?
AARTIDRUGS has a 5-year average Operating Profit Margin (OPM) of 13.80%, indicating the company's operational efficiency.
How is AARTIDRUGS quarterly performance?
Recent quarterly performance shows Aarti Drugs Ltd YoY Sales Growth of 9.10% and YoY Profit Growth of 29.33%.
What is the institutional holding pattern in AARTIDRUGS?
AARTIDRUGS has FII holding of 2.68% and DII holding of 9.90%. Significant institutional holding often suggests professional confidence in the Aarti Drugs Ltd stock.